FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

仅供研究使用。 完整免责声明 →

研究/Highlighting the promising preliminary results of retatrutide for obesity management through a systematic review and meta-analysis, emphasizing the need for further research.
返回研究图书馆
retatrutidetriple hormone receptor agonist

Highlighting the promising preliminary results of retatrutide for obesity management through a systematic review and meta-analysis, emphasizing the need for further research.

May 16, 2026
Share

原始论文

Efficacy and safety of triple hormone receptor agonist retatrutide for the management of obesity: a systematic review and meta-analysis.

Tewari Jay et al.Expert review of clinical pharmacology2025
新兴研究

基于新兴研究。这些发现很有前景,但需要进一步验证。

关于此分析

本文将上述源论文的研究成果分解成肽类研究社区易于理解的语言。我们的目标是突出最值得关注的内容 — 实用意义、证据强度以及对正在进行的研究的影响。

Novel Triple Hormone Receptor Agonist Shows Promise in Obesity Management

Published: May 16, 2026 | Source: Expert review of clinical pharmacology (2025) | Category: retatrutide, triple hormone receptor agonist

Overview

A recent systematic review and meta-analysis published in Expert Review of Clinical Pharmacology highlights the potential of retatrutide, a novel triple hormone receptor agonist, for managing obesity. The study synthesizes data from four randomized controlled trials (RCTs) and suggests that retatrutide is more effective than placebo in reducing obesity-related outcomes, with minimal safety concerns.

Study Background

Obesity management has long been a challenge due to the complexity of metabolic pathways involved. Retatrutide, by targeting multiple hormone receptors simultaneously, offers a promising approach to weight loss. This meta-analysis aimed to consolidate existing evidence on retatrutide's efficacy and safety profile, providing insights for both researchers and clinicians.

What the Research Found

The systematic review included four RCTs that compared retatrutide with placebo in managing obesity. The analysis revealed a dose-dependent relationship between retatrutide dosage and weight loss outcomes. Specifically, participants receiving 12 mg of retatrutide experienced the most significant reductions in body mass index (BMI) and waist circumference compared to those on lower doses or placebo.

In terms of safety, no major adverse events were reported with retatrutide use, indicating a comparable safety profile to the control group. This suggests that retatrutide may be well-tolerated by patients undergoing obesity management treatments.

What This Means for Peptide Users

While these findings are encouraging, it is important to note that retatrutide is still in its early stages of clinical development. The current data supports further investigation into this peptide's potential benefits and long-term safety profile. For individuals considering the use of peptides like retatrutide, consulting with a healthcare provider remains crucial.

Limitations and Caveats

The study’s reliance on only four RCTs limits the generalizability of its findings. Additionally, the lack of longer-term data means that potential side effects or benefits over extended periods remain unknown. These limitations underscore the need for larger, more comprehensive clinical trials to validate retatrutide's efficacy and safety.

How This Compares to Previous Research

Previous studies on single hormone receptor agonists have shown mixed results in terms of both efficacy and safety. Retatrutide’s multi-receptor approach appears to offer a promising alternative by potentially enhancing therapeutic effects while maintaining a favorable safety profile. However, direct comparisons with other peptides are limited due to the novelty of retatrutide.

Our Analysis

PeptideVault's analysis suggests that this meta-analysis provides valuable preliminary evidence supporting retatrutide’s potential as an obesity management tool. The study adheres to rigorous methodologies and presents clear findings regarding efficacy and safety. Nonetheless, the need for further research is evident to address current limitations and provide a more robust understanding of retatrutide's long-term effects.

Key Takeaways

  • Retatrutide shows promise in reducing obesity-related outcomes compared to placebo.
  • A dose-dependent relationship exists between retatrutide dosage and efficacy.
  • Current safety data suggests that retatrutide is well-tolerated, but more research is needed for comprehensive understanding.
  • Consultation with healthcare providers remains essential for individuals considering peptide therapy.

Original Source

Citation: Tewari Jay, Qidwai Khalid Ahmad, Tewari Ajoy et al. (2025). Efficacy and safety of triple hormone receptor agonist retatrutide for the management of obesity: a systematic review and meta-analysis.. Expert review of clinical pharmacology. DOI: 10.1080/17512433.2025.2450254

Access:

---

This article is for informational and research purposes only. PeptideVault summarizes and analyzes published research. Always consult a licensed healthcare provider.

编辑注释

此分析由Peptide Contacts研究团队准备。鼓励读者查阅 完整源论文 以获取完整方法和数据。 原始出版物可在 PubMed.

相关研究

Comments

Sign in to join the discussion

此分析基于同行评审研究仅用于教育目的。并不构成医疗建议。在使用任何肽类疗法之前,请咨询合格的医疗服务提供者。